(Reuters) - Shares of the Cambridge, Massachusetts-based biotechnology company plunged 24 percent in pre-market trading after the U.S. Food and Drug Administration placed further development of the drug in the United States on hold.
While Idenix said it will discuss the issue with its partner, Swiss drugmaker Novartis AG , the company said it does not believe the drug can be rescued.
Read more at Reuters.com Hot Stocks News
While Idenix said it will discuss the issue with its partner, Swiss drugmaker Novartis AG , the company said it does not believe the drug can be rescued.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment